Ultragenyx Pharmaceutical
(NASDAQ) RARE
Ultragenyx Pharmaceutical Financials at a Glance
Market Cap
$1.93B
Revenue (TTM)
$672.72M
Net Income (TTM)
$575.44M
EPS (TTM)
$-5.84
P/E Ratio
-3.43
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$19.39
Volume
54,239
Open
$19.86
Price
$19.39
Volume
54,239
Open
$19.86
Previous Close
$19.39
Daily Range
$19.10 - $20.05
52-Week Range
$18.29 - $42.37
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$19.39
Volume
54,239
Open
$19.86
Previous Close
$19.39
Daily Range
$19.10 - $20.05
52-Week Range
$18.29 - $42.37
RARE News
RARE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ultragenyx Pharmaceutical
Industry
Biotechnology
Sector
Health CareEmployees
1,371
CEO
Emil D. Kakkis, MD, PhD
Website
www.ultragenyx.comHeadquarters
Novato, CA 94949, US
RARE Financials
Key Financial Metrics (TTM)
Gross Margin
84%
Operating Margin
-80%
Net Income Margin
-86%
Return on Equity
-657%
Return on Capital
-47%
Return on Assets
-38%
Earnings Yield
-29.15%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.93B
Shares Outstanding
96.63M
Volume
54.24K
Short Interest
0.00%
Avg. Volume
2.93M
Financials (TTM)
Gross Profit
$564.00M
Operating Income
$535.00M
EBITDA
$500.00M
Operating Cash Flow
$466.00M
Capital Expenditure
$6.00M
Free Cash Flow
$472.00M
Cash & ST Invst.
$693.00M
Total Debt
$1.28B
Ultragenyx Pharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$207.00M
+25.5%
Gross Profit
$178.00M
+20.3%
Gross Margin
85.99%
N/A
Market Cap
$1.93B
N/A
Market Cap/Employee
$1.49M
N/A
Employees
1,294
N/A
Net Income
$129.00M
+3.3%
EBITDA
$105.22M
+3.3%
Quarterly Fundamentals
Net Cash
$583.00M
-202.3%
Accounts Receivable
$159.00M
+30.5%
Inventory
$52.00M
+15.5%
Long Term Debt
$1.20B
+3877.8%
Short Term Debt
$81.00M
+686.6%
Return on Assets
-37.56%
N/A
Return on Invested Capital
-46.67%
N/A
Free Cash Flow
$100.77M
-25.7%
Operating Cash Flow
$99.83M
-25.6%